Table 1 Baseline characteristics of the cohort
Total n = 388 | |
|---|---|
Variable | n (%), mean (±SD) or median (IQR) |
Age, years | 65.3 (±12.6) |
Female gender, n (%) | 143 (36.9) |
Follow-up duration, years | 6.62 (3.76–6.64) |
Vintage, years | 5.79 (2.93–12.12) |
Systolic BP, mmHg | 146.7 (±20.3) |
Diastolic BP, mmHg | 77.3 (±13.8) |
BMI, kg/m2 | 21.7 (±3.5) |
CTR, % | 49.0 (±5.3) |
Single-pool Kt/V | 1.44 (±0.27) |
ABI | 1.10 (0.99–1.17) |
Smoking habits, n (%) | 64 (16.5) |
RAS inhibitor, n (%) | 207 (53.3) |
Statin, n (%) | 79 (20.4) |
Chronic kidney disease etiology, n (%) | |
Diabetic nephropathy | 136 (35.1) |
Hypertensive disease | 31 (8.0) |
Glomerulonephritis | 118 (30.4) |
Polycystic kidney disease | 10 (2.6) |
Others | 93 (24.0) |
Comorbid conditions, n (%) | |
Coronary artery disease (CAD) | 56 (14.4) |
Stroke | 64 (16.5) |
Peripheral Arterial Disease | 81 (20.9) |
Active cancer | 20 (5.2) |
Rheumatoid arthritis (RA) | 5 (1.3) |
Diabetes mellitus (DM) | 159 (41.0) |
Hypertension | 319 (82.2) |
Dyslipidemia | 198 (51.0) |
Laboratory findings | |
WBC, /μl | 5626 (±1666) |
hs-CRP, mg/l | 0.708 (0.295–1.828) |
Hemoglobin, g/dl | 10.7 (±1.1) |
Plt, 104/μl | 16.4 (±4.7) |
Albumin, g/dl | 3.8 (±0.33) |
BUN, mg/dl | 61.0 (±14.7) |
Cr, mg/dl | 10.9 (±2.6) |
Whole-PTH, pg/ml | 45 (24–92) |
aCa, mg/dl | 9.4 (±0.72) |
IP, mg/dl | 5.5 (±1.2) |
LDL-cholesterol, mg/dl | 79.3 (±23.6) |
TG, mg/dl | 84 (59–126) |
CPT, ng/ml | 6108 (4017–8906) |